Nephrology Daily Report: 01/15/2024

A Phase 2 randomized controlled trial investigated the effect of Cemdisiran in 31 patients with IgA nephropathy characterized by urine protein ≥1 g/24 hours and a high risk of kidney disease progression (1). The study found that Cemdisiran-treated patients experienced a significant reduction in proteinuria: a placebo-adjusted geometric mean change in 24-hour urine protein-to-creatinine ratio (UPCR) of -37.4% (cemdisiran-adjusted geometric mean ratio to baseline [SEM], 0.69 [0.10]) at week 32. Spot UPCR showed a consistent placebo-adjusted change of -45.8% (cemdisiran-adjusted geometric mean ratio to baseline [SEM], 0.73 [0.11]). Additionally, there was a mean change in serum C5 level of -98.7% (1.2) with Cemdisiran compared to 25.2% (57.7) with placebo. Most adverse events were mild or moderate, with the most common being injection-site reaction (41%). These findings indicate that Cemdisiran significantly reduces proteinuria and is well tolerated in patients with IgA nephropathy.

Reference

Barratt J, Liew A, Yeo SC, Fernström A, Barbour SJ, Sperati CJ, Villanueva R, Wu MJ, Wang D, Borodovsky A, Badri P, Yureneva E, Bhan I, Cattran D; Cemdisiran Phase 2 Study Investigators and Collaborators. Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2024 Jan 15. doi: 10.2215/CJN.0000000000000384. Epub ahead of print. PMID: 38214599.